Merck: promising results in melanoma treatment
With a median follow-up of around three years (34.9 months), V940 + Keytruda delivered 'a clinically significant and durable improvement in recurrence-free survival', the study's primary endpoint, reducing the risk of recurrence or death by 49% compared to Keytruda alone.
In addition, V940 + Keytruda showed a significant improvement in distant metastasis-free survival (DMFS), a key secondary endpoint of the study, compared with Keytruda alone, reducing the risk of developing distant metastases or death by 62%.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction